Transcription factor and uses therefor
AssigneeThe General Hospital Corporation
InventorsJoel F. Habener, Christopher P. Miller
Life of this patent
Estimating the term…
Abstract
The invention features a novel recombinant polypeptide that transactivates the somatostatin promoter, the polypeptide being present in pancreatic duct cells and not present in pancreatic .alpha.-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.
Claims6
A recombinant polypeptide that transactivates the somatostatin promoter, the natural analog of the polypeptide being present in pancreatic duct cells and not present in pancreatic .alpha.-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.
A recombinant protein comprising the amino acid sequence of IDX-1.
A method of treating diabetes comprising administering to a patient in need thereof a recombinant polypeptide that transactivates the somatostatin promoter, the natural analog of said polypeptide being present in pancreatic duct cells and not present in pancreatic .alpha.-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd, the polypeptide being administered in an amount and for a time sufficient to provide an effective level of endogenous insulin in the patient.
A recombinant polypeptide that transactivates the somatostatin promoter, the natural analog of the polypeptide being present in pancreatic .beta.-cells and not present in pancreatic .alpha.-cells, the polypeptide being encoded by a gene which encodes a protein on the order of 31 kd.
Dependencies are inferred from the claim text.